Hyo-Bin Kim1, Chang-Keun Kim1, Koji Iijima2, Takao Kobayashi2, Hirohito Kita3. 1. Department of Pediatrics, Asthma & Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea. 2. Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN. 3. Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN. Electronic address: kita.hirohito@mayo.edu.
Abstract
BACKGROUND: Microarray technology offers a new opportunity to gain insight into global gene and protein expression profiles in asthma. To identify novel factors produced in the asthmatic airway, we analyzed sputum samples by using a membrane-based human cytokine microarray technology in patients with bronchial asthma (BA). METHODS: Induced sputum was obtained from 28 BA subjects, 20 nonasthmatic atopic control (AC) subjects, and 38 nonasthmatic nonatopic normal control (NC) subjects. The microarray samples of subjects were randomly selected from nine BA subjects, three AC subjects, and six NC subjects. Sputum supernatants were analyzed using a custom human cytokine array (RayBio Custom Human Cytokine Array; RayBiotech; Norcross, GA) designed to analyze 79 specific cytokines simultaneously. The levels of growth-regulated oncogene (GRO)-alpha, eotaxin-2, and pulmonary and activation-regulated chemokine (PARC)/CCL18 were measured by sandwich enzyme-linked immunosorbent assays (ELISAs), and eosinophil-derived neurotoxin (EDN) was measured by radioimmunoassay. RESULTS: By microarray, the signal intensities for GRO-alpha, eotaxin-2, and PARC were significantly higher in BA subjects than in AC and NC subjects (p = 0.036, p = 0.042, and p = 0.033, respectively). By ELISA, the sputum PARC protein levels were significantly higher in BA subjects than in AC and NC subjects (p < 0.0001). Furthermore, PARC levels correlated significantly with sputum eosinophil percentages (r = 0.570, p < 0.0001) and the levels of EDN (r = 0.633, p < 0.0001), the regulated upon activation, normal T cell expressed and secreted cytokine (r = 0.440, p < 0.001), interleukin-4 (r = 0.415, p < 0.01), and interferon-gamma (r = 0.491, p < 0.001). CONCLUSIONS: By a nonbiased screening approach, a chemokine, PARC, is elevated in sputum specimens from patients with asthma. PARC may play important roles in development of airway eosinophilic inflammation in asthma.
BACKGROUND: Microarray technology offers a new opportunity to gain insight into global gene and protein expression profiles in asthma. To identify novel factors produced in the asthmatic airway, we analyzed sputum samples by using a membrane-based humancytokine microarray technology in patients with bronchial asthma (BA). METHODS: Induced sputum was obtained from 28 BA subjects, 20 nonasthmatic atopic control (AC) subjects, and 38 nonasthmatic nonatopic normal control (NC) subjects. The microarray samples of subjects were randomly selected from nine BA subjects, three AC subjects, and six NC subjects. Sputum supernatants were analyzed using a custom humancytokine array (RayBio Custom HumanCytokine Array; RayBiotech; Norcross, GA) designed to analyze 79 specific cytokines simultaneously. The levels of growth-regulated oncogene (GRO)-alpha, eotaxin-2, and pulmonary and activation-regulated chemokine (PARC)/CCL18 were measured by sandwich enzyme-linked immunosorbent assays (ELISAs), and eosinophil-derived neurotoxin (EDN) was measured by radioimmunoassay. RESULTS: By microarray, the signal intensities for GRO-alpha, eotaxin-2, and PARC were significantly higher in BA subjects than in AC and NC subjects (p = 0.036, p = 0.042, and p = 0.033, respectively). By ELISA, the sputum PARC protein levels were significantly higher in BA subjects than in AC and NC subjects (p < 0.0001). Furthermore, PARC levels correlated significantly with sputum eosinophil percentages (r = 0.570, p < 0.0001) and the levels of EDN (r = 0.633, p < 0.0001), the regulated upon activation, normal T cell expressed and secreted cytokine (r = 0.440, p < 0.001), interleukin-4 (r = 0.415, p < 0.01), and interferon-gamma (r = 0.491, p < 0.001). CONCLUSIONS: By a nonbiased screening approach, a chemokine, PARC, is elevated in sputum specimens from patients with asthma. PARC may play important roles in development of airway eosinophilic inflammation in asthma.
Authors: S Ying; D S Robinson; Q Meng; L T Barata; A R McEuen; M G Buckley; A F Walls; P W Askenase; A B Kay Journal: J Immunol Date: 1999-10-01 Impact factor: 5.422
Authors: A Spanevello; G B Migliori; A Sharara; L Ballardini; P Bridge; P Pisati; M Neri; P W Ind Journal: Clin Exp Allergy Date: 1997-10 Impact factor: 5.018
Authors: Annette T Hastie; Wendy C Moore; Deborah A Meyers; Penny L Vestal; Huashi Li; Stephen P Peters; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2010-04-15 Impact factor: 10.793
Authors: Sangita P Patil; Juan P Wisnivesky; Paula J Busse; Ethan A Halm; Xiu-Min Li Journal: Ann Allergy Asthma Immunol Date: 2011-01-14 Impact factor: 6.347
Authors: Douglas A Plager; Jane C Kahl; Yan W Asmann; Allan E Nilson; John F Pallanch; Oren Friedman; Hirohito Kita Journal: PLoS One Date: 2010-07-06 Impact factor: 3.240
Authors: M L Gavala; E A B Kelly; S Esnault; S Kukreja; M D Evans; P J Bertics; G L Chupp; N N Jarjour Journal: Clin Exp Allergy Date: 2013-02 Impact factor: 5.018
Authors: Jose L Gomez; Xiting Yan; Carole T Holm; Nicole Grant; Qing Liu; Lauren Cohn; Vera Nezgovorova; Deborah A Meyers; Eugene R Bleecker; Gina M Crisafi; Nizar N Jarjour; Linda Rogers; Joan Reibman; Geoffrey L Chupp Journal: Eur Respir J Date: 2017-10-12 Impact factor: 16.671
Authors: William R Berrington; Chhatra B Kunwar; Kapil Neupane; Susan J F van den Eeden; James C Vary; Glenna J Peterson; Richard D Wells; Annemieke Geluk; Deanna A Hagge; Thomas R Hawn Journal: PLoS Negl Trop Dis Date: 2014-11-20
Authors: Alessandra Micera; Antonio Di Zazzo; Graziana Esposito; Roberto Sgrulletta; Virginia L Calder; Stefano Bonini Journal: Biomed Res Int Date: 2016-02-17 Impact factor: 3.411